Biotech entity
The clearest coverage concentration is pharma: 7 of 9 stories, with the rest divided among 2 other categories. AstraZeneca is most often covered alongside FDA, which appears in 3 of these 9 stories. Sentiment skews less negative than the wider beat, at 11% negative against 19% across all 616 Biotech stories in the same window.
Last mentioned: Sep 8, 2026
Entity pulse
Coverage balance Balanced directional read. Positive and negative coverage are within 0 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
The clearest coverage concentration is pharma: 7 of 9 stories, with the rest divided among 2 other categories. AstraZeneca is most often covered alongside FDA, which appears in 3 of these 9 stories. Sentiment skews less negative than the wider beat, at 11% negative against 19% across all 616 Biotech stories in the same window. The 163-day window averages about 0.4 stories each week. The busiest single day carried 2. They are less corroborated than the beat average, carrying 3.4 original sources each against 3.7 for the same window. Their average consequence score of 6.2 sits level with the 6.2 recorded across the beat in that window. We currently track 9 Biotech stories that mention AstraZeneca, published between February 22, 2026 and August 3, 2026.
Computed from the 9 stories linked to this entity, with beat comparisons drawn from all 616 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering AstraZeneca. Shared-story counts are live from our verified record — not editorial picks.
The potential merger could dramatically reshape oncology and cardiovascular R&D pipelines, triggering a wave of consolidation among biotech firms seeking scale to compete with the new behemoth.
Source: eadt.co.uk · chardandilminsternews.co.uk
The merger would unite two cancer powerhouses, combining blockbusters like Opdivo and Tagrisso into a pipeline with more than 100 clinical programs. Biotech investors see a fusion of immuno-oncology and targeted therapy leadership.
Source: CNBC · finance.yahoo.com
The Tenth Circuit's decision reaffirms clinical trial sponsors' liability protections under the PREP Act, but a pending waiver analysis could impact how pharmaceutical companies draft informed consent forms.
Source: saltlakecitysun.com · utahindependent.com
Mineralys Therapeutics (MLYS) reported a narrower-than-expected Q4 2025 loss and confirmed the FDA's acceptance of its New Drug Application for lorundrostat. The company is now pivoting toward commercial readiness for its lead hypertension candidate while maintaining a robust clinical pipeline in chronic kidney disease.
Ipsen has appointed Michelle C. Werner as Executive Vice President and President of North America, effective March 2026. A veteran of AstraZeneca and former CEO of Alltrna, Werner is tasked with accelerating growth in Ipsen's largest market across its oncology, rare disease, and neuroscience portfolios.
Roche shares declined following the announcement that its oral SERD, giredestrant, failed to meet the primary endpoint in a pivotal Phase III trial for advanced breast cancer. The setback marks a significant blow to Roche's efforts to regain dominance in the HR-positive, HER2-negative oncology market.
Lexicon Pharmaceuticals is set to report Q4 2025 results, with investors laser-focused on the commercial trajectory of heart failure drug Inpefa and the regulatory path for sotagliflozin in Type 1 Diabetes. The briefing examines the company's financial health and the strategic importance of its neuropathic pain candidate, LX9211.
AstraZeneca CEO Pascal Soriot's total compensation for 2025 reached £17.7 million, driven by significant performance-linked bonuses. The payout reinforces Soriot's position as one of the highest-paid executives in the FTSE 100 as the company pursues an ambitious $80 billion revenue target by 2030.
A widespread media narrative is challenging the clinical hegemony of statins, highlighting a perceived lack of transparency regarding side effects and alternative cardiovascular therapies. This shift in public discourse signals a growing demand for patient autonomy that could impact the long-term market share of traditional lipid-lowering blockbusters.
Source: kingstonthisweek.com · shorelinebeacon.com
AstraZeneca is linked from 9 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
